Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second-look resection

Journal Article · Mon Jan 15 00:00:00 EST 1990 · Cancer (Philadelphia); (USA)

DOI:https://doi.org/10.1002/1097-0142(19900115)65:2<211::AID-CNCR2820650205>3.0.CO;2-G· OSTI ID:7194738

Tang, Z Y; Liu, K D; Bao, Y M; Lu, J Z; Yu, Y Q; Ma, Z C; Zhou, X D; Yang, R; Gan, Y H; Lin, Z Y ^[1]

---

1. Shanghai Medical Univ. (China)

Experimental study using nude mice human hepatocellular carcinoma (HCC) xenograft indicated that the combination treatment with iodine 131 (131I)-anti-human HCC isoferritin (131I-isoFtAb), cisplatin, and mixed bacterial vaccine (MBV) yielded better inhibition rate as compared with double combination or 131I-isoFtAb alone. Based on these findings, 25 patients with surgically proven nonresectable and pathologically proven HCC have been treated by radioimmunotherapy using 131I-isoFtAb intrahepatic arterial infusion as a part of multimodality treatment. Of the 25 patients, seven (28.0%) received second-look resection after marked shrinkage of tumor. The 1-year survival was 52.5% (12/23) and 2-year survival 27.7% (five of 18) in the entire series. Of the five patients with 2-year survival, four were in the second-look resection group. Patients with tumor less than or equal to 8 cm showed higher second-look resection rate (62.5% versus 11.8%) and 1-year survival (85.7% versus 37.5%) as compared with tumor greater than 8 cm. Mixed bacterial vaccine as adjuvant immunotherapy seemed effective to prolong survival. The 2-year survival was higher in patients with second-look resection as compared with those without (75.0% versus 14.3%). Thus, radioimmunotherapy using 131I-isoFtAb might be one of the modalities of choice, particularly in the conversion of nonresectable to resectable HCC in a well-designed multimodality treatment regimen.

• OSTI ID: 7194738
• Journal Information: Cancer (Philadelphia); (USA), Vol. 65:2; ISSN 0008-543X
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
HEPATOMAS
RADIOIMMUNOTHERAPY
ANTIBODIES
COMBINED THERAPY
FERRITIN
IODINE 131
LIVER
MICE
SURGERY
SURVIVAL CURVES
ANIMALS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
COMPLEXES
DAYS LIVING RADIOISOTOPES
DIGESTIVE SYSTEM
DISEASES
GLANDS
IMMUNOLOGY
IMMUNOTHERAPY
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
IRON COMPLEXES
ISOTOPES
MAMMALS
MEDICINE
METALLOPROTEINS
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANIC COMPOUNDS
ORGANS
PROTEINS
RADIOIMMUNOLOGY
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
RODENTS
THERAPY
TRANSITION ELEMENT COMPLEXES
VERTEBRATES
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)
550600 - Medicine